

Evi S Lianidou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6126424/publications.pdf>

Version: 2024-02-01

163
papers

8,161
citations

31902

53
h-index

53109

85
g-index

166
all docs

166
docs citations

166
times ranked

9555
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non-Small Cell Lung Cancer by Quantitative Real-Time RT-PCR. <i>Clinical Chemistry</i> , 2008, 54, 1696-1704.	1.5	415
2	Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 3756-3762.	0.8	268
3	Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2177-2184.	0.8	246
4	Different Prognostic Value of Cytokeratin-19 mRNA-Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5194-5202.	0.8	238
5	Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges. <i>Clinical Chemistry</i> , 2011, 57, 1242-1255.	1.5	235
6	Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2593-2600.	3.2	220
7	Quantification of Circulating miRNAs in Plasma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 827-834.	1.2	186
8	Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. <i>Clinical Biochemistry</i> , 2010, 43, 150-158.	0.8	184
9	Clinical evaluation of microRNA expression profiling in non small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 388-396.	0.9	179
10	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1923-1933.	0.6	153
11	Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. <i>Rna</i> , 2009, 15, 1443-1461.	1.6	147
12	DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2011, 57, 1169-1177.	1.5	145
13	SOX17 Promoter Methylation in Circulating Tumor Cells and Matched Cell-Free DNA Isolated from Plasma of Patients with Breast Cancer. <i>Clinical Chemistry</i> , 2013, 59, 270-279.	1.5	125
14	ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 1500-1510.	3.2	125
15	Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. <i>Clinical Cancer Research</i> , 2003, 9, 5145-51.	3.2	122
16	Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA-Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 8185-8194.	3.2	121
17	Molecular Characterization of Circulating Tumor Cells in Breast Cancer by a Liquid Bead Array Hybridization Assay. <i>Clinical Chemistry</i> , 2011, 57, 421-430.	1.5	118
18	Liquid biopsies. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 219-232.	1.5	117

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. <i>Science of the Total Environment</i> , 2022, 804, 150151.	3.9	116
20	Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. <i>Clinical Biochemistry</i> , 2006, 39, 727-731.	0.8	113
21	Hypoxia-inducible factor-1 \pm and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R84.	2.2	111
22	Circulating tumor cells as promising novel biomarkers in solid cancers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 160-171.	2.7	111
23	Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. <i>Oncogene</i> , 2019, 38, 3387-3401.	2.6	109
24	Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. <i>Clinical Chemistry</i> , 2020, 66, 149-160.	1.5	100
25	Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. <i>Translational Research</i> , 2019, 205, 77-91.	2.2	98
26	Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. <i>BMC Cancer</i> , 2011, 11, 422.	1.1	97
27	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. <i>Scientific Reports</i> , 2016, 6, 39736.	1.6	96
28	Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. <i>Annals of Oncology</i> , 2003, 14, 849-855.	0.6	95
29	Lung cancer epigenetics: emerging biomarkers. <i>Biomarkers in Medicine</i> , 2013, 7, 49-58.	0.6	89
30	Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 134, 116125.	5.8	88
31	Application of terbium sensitized fluorescence for the determination of fluoroquinolone antibiotics pefloxacin, ciprofloxacin and norfloxacin in serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 15, 1839-1844.	1.4	85
32	Prognostic Significance of Metastasis-Related MicroRNAs in Early Breast Cancer Patients with a Long Follow-up. <i>Clinical Chemistry</i> , 2014, 60, 197-205.	1.5	84
33	A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. <i>International Journal of Cancer</i> , 2006, 119, 1654-1659.	2.3	81
34	The Role of CTCs as Tumor Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 341-367.	0.8	80
35	Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. <i>Clinical Biochemistry</i> , 2006, 39, 879-887.	0.8	79
36	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Molecular Therapy</i> , 2015, 23, 1748-1758.	3.7	73

#	ARTICLE	IF	CITATIONS
37	Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 663-671.	2.7	71
38	CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. <i>Clinical Biochemistry</i> , 2013, 46, 235-240.	0.8	70
39	Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2014, 110, 2054-2062.	2.9	68
40	Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2015, 185, 693-703.	1.9	68
41	Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 778, 46-51.	0.4	68
42	Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 297-306.	1.5	67
43	SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1385-93.	1.4	66
44	Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 186-197.	1.4	65
45	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 2426-2432.	2.9	60
46	miRNA-21 as a novel therapeutic target in lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2016, 7, 19.	1.3	59
47	Circulating tumor cells as emerging tumor biomarkers in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1579-90.	1.4	57
48	Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1505-10.	1.4	55
49	miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 136-144.	1.2	55
50	<i>PIK3CA</i> hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. <i>Molecular Oncology</i> , 2019, 13, 2515-2530.	2.1	55
51	Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Primary Breast Tumors and Corresponding Circulating Tumor Cells. <i>Molecular Cancer Research</i> , 2013, 11, 1248-1257.	1.5	54
52	<i>PIK3CA</i> Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5823-5834.	3.2	54
53	Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. <i>Cancer Microenvironment</i> , 2014, 7, 117-131.	3.1	54
54	Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients. <i>Clinical Chemistry</i> , 2016, 62, 1002-1011.	1.5	54

#	ARTICLE	IF	CITATIONS
55	Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. <i>Oncology Letters</i> , 2016, 12, 748-756.	0.8	51
56	<i>RASSF1A</i> promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 21429-21443.	0.8	51
57	MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. <i>Cancer Medicine</i> , 2016, 5, 656-664.	1.3	50
58	Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1591-603.	1.4	49
59	Molecular Detection and Prognostic Value of Circulating Cytokeratin-19 Messenger RNA ⁺ and HER2 Messenger RNA ⁺ Positive Cells in the Peripheral Blood of Women with Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 883-889.	1.1	48
60	Gene expression profiling and DNA methylation analyses of CTCs. <i>Molecular Oncology</i> , 2016, 10, 431-442.	2.1	45
61	Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. <i>Cells</i> , 2019, 8, 652.	1.8	44
62	Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook. <i>Molecular Oncology</i> , 2021, 15, 1683-1700.	2.1	43
63	Comparative study of fluorescent ternary terbium complexes. Application in enzyme amplified fluorimetric immunoassay for α -fetoprotein. <i>Analytica Chimica Acta</i> , 1996, 335, 177-184.	2.6	42
64	Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. <i>Cancer Letters</i> , 2002, 185, 61-70.	3.2	42
65	Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R20.	2.2	42
66	ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 355-360.	0.6	42
67	Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies. <i>Clinical Chemistry</i> , 2018, 64, 1522-1533.	1.5	42
68	Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. <i>Annals of Oncology</i> , 2009, 20, 1020-1025.	0.6	40
69	Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 780.	1.7	40
70	Real-Time RT-PCR Quantification of Human Telomerase Reverse Transcriptase Splice Variants in Tumor Cell Lines and Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2007, 53, 53-61.	1.5	39
71	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 594-606.	1.1	38
72	PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis Method. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 697-704.	1.2	37

#	ARTICLE	IF	CITATIONS
73	Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows. <i>Clinical Chemistry</i> , 2019, 65, 1132-1140.	1.5	37
74	Determination of tumor necrosis factor- $\hat{I}\pm$ (TNF- $\hat{I}\pm$) in serum by a highly sensitive enzyme amplified lanthanide luminescence immunoassay. <i>Clinical Biochemistry</i> , 1999, 32, 241-247.	0.8	36
75	Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. <i>Oncotarget</i> , 2017, 8, 72054-72068.	0.8	36
76	Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6551.	1.6	34
77	Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. <i>International Journal of Cancer</i> , 2009, 125, 2887-2892.	2.3	33
78	Quantitative Real-Time Reverse Transcription-PCR Study of the Expression of Vascular Endothelial Growth Factor (VEGF) Splice Variants and VEGF Receptors (VEGFR-1 and VEGFR-2) in Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2007, 53, 1433-1439.	1.5	32
79	Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. <i>Scientific Reports</i> , 2021, 11, 2313.	1.6	32
80	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020, 10, 214.	1.1	31
81	Synchronous scanning second derivative spectrofluorimetry for the simultaneous determination of diflunisal and salicylic acid added to serum and urine as ternary complexes with terbium and EDTA. <i>Analytica Chimica Acta</i> , 1996, 320, 107-114.	2.6	29
82	Prognostic significance of RASSF1A promoter methylation in operable breast cancer. <i>Clinical Biochemistry</i> , 2009, 42, 970-975.	0.8	29
83	Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) $\hat{I}\pm+\hat{I}^2+$ transcript in estrogen receptor-positive MCF-7 breast cancer cells. <i>Clinical Biochemistry</i> , 2009, 42, 1358-1362.	0.8	29
84	Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies. <i>Analytical Chemistry</i> , 2019, 91, 13105-13111.	3.2	29
85	Circulating Tumor Cells—New Challenges Ahead. <i>Clinical Chemistry</i> , 2012, 58, 805-807.	1.5	28
86	Exosomes: A Cancer Theranostics Road Map. <i>Public Health Genomics</i> , 2017, 20, 116-125.	0.6	26
87	Second derivative synchronous scanning fluorescence spectrometry as a sensitive detection technique in immunoassays. Application to the determination of $\hat{I}\pm$ -fetoprotein. <i>Analytica Chimica Acta</i> , 1994, 290, 159-165.	2.6	24
88	Real-Time Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor Splice Variants. <i>Clinical Chemistry</i> , 2005, 51, 1518-1520.	1.5	23
89	The potential of ctDNA analysis in breast cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 54-72.	2.7	22
90	Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. <i>Clinical Biochemistry</i> , 2005, 38, 50-57.	0.8	21

#	ARTICLE	IF	CITATIONS
91	An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways. <i>Molecular Oncology</i> , 2015, 9, 1667-1677.	2.1	21
92	Expression pattern of androgen receptors, <i>AR-V7</i> and <i>AR-567es</i> , in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer. <i>Analyst</i> , 2019, 144, 6671-6680.	1.7	21
93	Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease. <i>Clinical Biochemistry</i> , 2008, 41, 82-87.	0.8	20
94	What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup ctDNA. <i>Clinica Chimica Acta</i> , 2021, 520, 168-171.	0.5	20
95	Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. <i>Molecular Oncology</i> , 2020, 14, 1001-1015.	2.1	19
96	Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. <i>Cancers</i> , 2021, 13, 2736.	1.7	19
97	Simple, rapid and sensitive spectrofluorimetric determination of diflunisal in serum and urine based on its ternary complex with terbium and EDTA. <i>Analytica Chimica Acta</i> , 1995, 300, 237-241.	2.6	18
98	HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. <i>Clinical Biochemistry</i> , 2006, 39, 942-946.	0.8	18
99	Circulating Tumor Cell Isolation: A Marathon Race Worth Running. <i>Clinical Chemistry</i> , 2014, 60, 287-289.	1.5	18
100	<i>KMT2C</i> promoter methylation in plasma circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 2412-2422.	2.1	18
101	HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study. <i>PLoS ONE</i> , 2019, 14, e0215984.	1.1	17
102	Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler. <i>Clinica Chimica Acta</i> , 2008, 390, 141-144.	0.5	16
103	Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000646.	2.0	16
104	Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for <i>PD-L1</i> Transcripts in Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2021, 67, 642-652.	1.5	16
105	RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer. <i>Diagnostics</i> , 2021, 11, 513.	1.3	15
106	Development of a quantitative luminometric hybridization assay for the determination of telomerase activity. <i>Clinical Biochemistry</i> , 2001, 34, 277-284.	0.8	14
107	A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of <i>CST6</i> promoter methylation in clinical samples. <i>BMC Cancer</i> , 2012, 12, 486.	1.1	14
108	PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients. <i>Cancers</i> , 2020, 12, 1188.	1.7	14

#	ARTICLE	IF	CITATIONS
109	Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382097327.	0.8	14
110	Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis. <i>Clinical Biochemistry</i> , 2010, 43, 178-185.	0.8	13
111	Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2009, 50, 401-409.	0.6	12
112	Molecular Characterization of Circulating Tumor Cells: Holy Grail for Personalized Cancer Treatment?. <i>Clinical Chemistry</i> , 2014, 60, 1249-1251.	1.5	12
113	Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). <i>Oral Oncology</i> , 2019, 94, 93-100.	0.8	12
114	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.	2.1	12
115	A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1395-1405.	1.5	12
116	Circulating Cancer Cells and Their Clinical Applications. <i>Clinical Chemistry</i> , 2011, 57, 1478-1484.	1.5	11
117	Molecular Assays for the Detection and Characterization of CTCs. <i>Recent Results in Cancer Research</i> , 2012, 195, 111-123.	1.8	11
118	Quantitative RT-PCR luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer. <i>Clinical Biochemistry</i> , 2001, 34, 651-659.	0.8	10
119	Effect of antineoplastic agents on the expression of human telomerase reverse transcriptase beta plus transcript in MCF-7 cells. <i>Clinical Biochemistry</i> , 2004, 37, 299-304.	0.8	10
120	Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis. <i>Clinica Chimica Acta</i> , 2016, 461, 156-164.	0.5	10
121	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of <i>BRAF</i> V600E mutation in plasma from melanoma patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1799-1807.	1.4	10
122	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. <i>Frontiers in Immunology</i> , 2021, 12, 746203.	2.2	10
123	Determination of <i>MYD88L265P</i> mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	2.5	10
124	Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4.	1.7	10
125	ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies. <i>Cancers</i> , 2021, 13, 556.	1.7	9
126	Liquid biopsy in ovarian cancer. <i>Advances in Clinical Chemistry</i> , 2020, 97, 13-71.	1.8	9

#	ARTICLE	IF	CITATIONS
127	DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. <i>Cancers</i> , 2021, 13, 5974.	1.7	9
128	Evaluation of viral concentration and extraction methods for SARS-CoV-2 recovery from wastewater using droplet digital and quantitative RT-PCR. <i>Case Studies in Chemical and Environmental Engineering</i> , 2022, 6, 100224.	2.9	9
129	Circulating Tumor Cells and Circulating Tumor DNA. , 2018, , 235-281.		8
130	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. <i>Cancers</i> , 2022, 14, 1574.	1.7	8
131	Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges. <i>Laboratory Medicine Online</i> , 2012, 2, 59.	0.0	7
132	USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer. <i>Cancers</i> , 2021, 13, 4607.	1.7	7
133	Enzymic fluorimetric determination of sulphated and non-sulphated primary bile acids in urine using a rapid solvolysis technique. <i>Analyt. Chem.</i> , 1988, 60, 1459.	1.7	6
134	Determination of ursodeoxycholic acid in serum by a new fluorometric enzymatic method using 7 β -hydroxysteroid dehydrogenase from <i>Clostridium absonum</i> . <i>Analytical Biochemistry</i> , 1989, 179, 341-346.	1.1	6
135	BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. <i>Clinical Biochemistry</i> , 1997, 30, 425-432.	0.8	6
136	Atypical Medullary Breast Carcinoma in a Family Carrying the 5382insC BRCA-1 Mutation. <i>Breast Journal</i> , 2003, 9, 260-262.	0.4	6
137	A pilot plasma-ctDNA ring trial for the Cobas [®] EGFR Mutation Test in clinical diagnostic laboratories. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e97-e101.	1.4	6
138	The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group "CNAPS/CTC for early detection of cancer". <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 821-829.	1.4	6
139	Development of a multiplexed PCR-coupled liquid bead array assay for vascular endothelial growth factor (VEGF) splice variants. <i>Clinical Biochemistry</i> , 2012, 45, 475-482.	0.8	5
140	Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer. <i>Clinical Biochemistry</i> , 2016, 49, 253-259.	0.8	5
141	Development and Validation of Multiplex Liquid Bead Array Assay for the Simultaneous Expression of 14 Genes in Circulating Tumor Cells. <i>Analytical Chemistry</i> , 2019, 91, 3443-3451.	3.2	5
142	Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. <i>Cancers</i> , 2021, 13, 2446.	1.7	5
143	Genetic counseling of medullary breast cancer patients. <i>Clinical Genetics</i> , 2004, 65, 343-344.	1.0	4
144	A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. <i>Clinica Chimica Acta</i> , 2015, 444, 303-309.	0.5	4

#	ARTICLE	IF	CITATIONS
145	Androgen Receptor and <i>PIM1</i> Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	1.0	4
146	Association between <i>SOX17</i> , <i>Wif-1</i> and <i>RASSF1A</i> promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e73-e75.	1.4	4
147	DNA and Histone Methylation in Lung Cancer. <i>Cancer Drug Discovery and Development</i> , 2017, , 403-436.	0.2	3
148	The Impact of Pre-analytical Factors on the Reliability of miRNA Measurements. <i>Current Pathobiology Reports</i> , 2019, 7, 29-33.	1.6	3
149	The Effect of Genomic DNA Contamination on the Detection of Circulating Long Non-Coding RNAs: The Paradigm of MALAT1. <i>Diagnostics</i> , 2021, 11, 1160.	1.3	3
150	Systemic hypertension augments, whereas insulin-dependent diabetes down-regulates, endothelin A receptor expression in the mammary artery in coronary artery disease patients. <i>Cardiology Journal</i> , 2009, 16, 348-54.	0.5	3
151	Determination of kinetic parameters for 3 β -hydroxysteroid dehydrogenase using the five major bile acids and their conjugates as substrates and correlation with their structure and solubility. <i>Analyst</i> , 1987, 112, 753-755.	1.7	2
152	Enzymatic Fluorimetric Determination of Ursodeoxycholic Acid in Urine Using <i>Clostridium Absonum</i> 7 β -Hydroxysteroid Dehydrogenase. <i>Analytical Letters</i> , 1989, 22, 2265-2280.	1.0	2
153	Advancing the education in molecular diagnostics: The IFCC-Initiative "Clinical Molecular Biology Curriculum" (C-CMBC); A ten-year experience. <i>Clinica Chimica Acta</i> , 2014, 436, 5-8.	0.5	2
154	Metastasis-related miRNAs: a new way to differentiate patients with higher risk?. <i>Future Oncology</i> , 2015, 11, 365-367.	1.1	2
155	Orexin-A Exerts Equivocal Role in Atherosclerosis Process Depending on the Duration of Exposure: In Vitro Study. <i>Nutrients</i> , 2020, 12, 53.	1.7	2
156	Development of a highly sensitive RT-PCR luminometric hybridization assay for human telomerase reverse-transcriptase beta-plus transcript. <i>Anticancer Research</i> , 2003, 23, 4821-9.	0.5	2
157	Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3237.	1.7	2
158	Fragment analysis of the p53 gene in ovarian tumors. <i>Clinical Biochemistry</i> , 1998, 31, 551-553.	0.8	1
159	Characterization of the BRCA1-like immunoreactivity of human seminal plasma. <i>Urology</i> , 1999, 54, 753-762.	0.5	1
160	Molecular Assays for the Detection and Molecular Characterization of CTCs. <i>Current Cancer Research</i> , 2016, , 47-74.	0.2	1
161	Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer. <i>Familial Cancer</i> , 2016, 15, 183-191.	0.9	0
162	Enumeration and Molecular Analysis of CTCs in Metastatic Disease: The Breast Cancer Model. <i>Cancer Drug Discovery and Development</i> , 2017, , 41-65.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Circulating Tumor Cells: A Noninvasive Liquid Biopsy in Cancer. , 2014, , 119-132.		0